<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>29(16)</volume><submitter>Madeo LF</submitter><pubmed_abstract>A ZnO-Graphene oxide nanocomposite (Z-G) was prepared in order to exploit the biomedical features of each component in a single anticancer material. This was achieved by means of an environmentally friendly synthesis, taking place at a low temperature and without the involvement of toxic reagents. The product was physicochemically characterized. The ZnO-to-GO ratio was determined through thermogravimetric analysis, while scanning electron microscopy and transmission electron microscopy were used to provide insight into the morphology of the nanocomposite. Using energy-dispersive X-ray spectroscopy, it was possible to confirm that the graphene flakes were homogeneously coated with ZnO. The crystallite size of the ZnO nanoparticles in the new composite was determined using X-ray powder diffraction. The capacity of Z-G to enhance the toxicity of the anticancer drug Paclitaxel towards breast cancer cells was assessed via a cell viability study, showing the remarkable anticancer activity of the obtained system. Such results support the potential use of Z-G as an anticancer agent in combination with a common chemotherapeutic like Paclitaxel, leading to new chemotherapeutic formulations.</pubmed_abstract><journal>Molecules (Basel, Switzerland)</journal><pagination>3770</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11357239</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>ZnO-Graphene Oxide Nanocomposite for Paclitaxel Delivery and Enhanced Toxicity in Breast Cancer Cells.</pubmed_title><pmcid>PMC11357239</pmcid><pubmed_authors>Curcio M</pubmed_authors><pubmed_authors>Cirillo G</pubmed_authors><pubmed_authors>Buchner B</pubmed_authors><pubmed_authors>Mertig M</pubmed_authors><pubmed_authors>Froeschke S</pubmed_authors><pubmed_authors>Tucci P</pubmed_authors><pubmed_authors>Wolf D</pubmed_authors><pubmed_authors>Ghunaim R</pubmed_authors><pubmed_authors>Iemma F</pubmed_authors><pubmed_authors>Asha AN</pubmed_authors><pubmed_authors>Schirmer C</pubmed_authors><pubmed_authors>Madeo LF</pubmed_authors><pubmed_authors>Hampel S</pubmed_authors></additional><is_claimable>false</is_claimable><name>ZnO-Graphene Oxide Nanocomposite for Paclitaxel Delivery and Enhanced Toxicity in Breast Cancer Cells.</name><description>A ZnO-Graphene oxide nanocomposite (Z-G) was prepared in order to exploit the biomedical features of each component in a single anticancer material. This was achieved by means of an environmentally friendly synthesis, taking place at a low temperature and without the involvement of toxic reagents. The product was physicochemically characterized. The ZnO-to-GO ratio was determined through thermogravimetric analysis, while scanning electron microscopy and transmission electron microscopy were used to provide insight into the morphology of the nanocomposite. Using energy-dispersive X-ray spectroscopy, it was possible to confirm that the graphene flakes were homogeneously coated with ZnO. The crystallite size of the ZnO nanoparticles in the new composite was determined using X-ray powder diffraction. The capacity of Z-G to enhance the toxicity of the anticancer drug Paclitaxel towards breast cancer cells was assessed via a cell viability study, showing the remarkable anticancer activity of the obtained system. Such results support the potential use of Z-G as an anticancer agent in combination with a common chemotherapeutic like Paclitaxel, leading to new chemotherapeutic formulations.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Aug</publication><modification>2025-04-26T11:44:24.386Z</modification><creation>2025-04-06T13:45:47.088Z</creation></dates><accession>S-EPMC11357239</accession><cross_references><pubmed>39202850</pubmed><doi>10.3390/molecules29163770</doi></cross_references></HashMap>